Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Cipla
Accenture
Moodys
Argus Health
Medtronic
Chubb
Covington

Generated: September 18, 2018

DrugPatentWatch Database Preview

Bristol Myers Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS, and when can generic versions of BRISTOL MYERS drugs launch?

BRISTOL MYERS has eighty-two approved drugs.

There are seventeen US patents protecting BRISTOL MYERS drugs.

Summary for Bristol Myers

Drugs and US Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb PRINCIPEN ampicillin/ampicillin trihydrate CAPSULE;ORAL 061392-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb AMITID amitriptyline hydrochloride TABLET;ORAL 086454-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers QUESTRAN cholestyramine POWDER;ORAL 016640-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-003 Dec 31, 2002 DISCN No No 7,135,465*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb RUBRAMIN PC cyanocobalamin INJECTABLE;INJECTION 006799-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET, TABLET;ORAL 021387-004 Jun 24, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-003 Dec 31, 2002 4,978,655*PED ➤ Try a Free Trial
Bristol Myers Squibb STADOL butorphanol tartrate SPRAY, METERED;NASAL 019890-001 Dec 12, 1991 4,464,378 ➤ Try a Free Trial
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET;ORAL 021387-006 Jun 24, 2003 5,030,447*PED ➤ Try a Free Trial
Bristol Myers Squibb PRAVACHOL pravastatin sodium TABLET;ORAL 019898-004 Mar 22, 1993 5,622,985*PED ➤ Try a Free Trial
Bristol Myers Squibb MONOPRIL-HCT fosinopril sodium; hydrochlorothiazide TABLET;ORAL 020286-002 Nov 30, 1994 4,384,123 ➤ Try a Free Trial
Bristol Myers Squibb BUSPAR buspirone hydrochloride TABLET;ORAL 018731-001 Sep 29, 1986 5,015,646*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BRISTOL MYERS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28

Non-Orange Book US Patents for Bristol Myers

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,691,846 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Try a Free Trial
6,989,391 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Try a Free Trial
7,371,761 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Try a Free Trial
RE38629 Solid oral dosage form comprising a combination of metformin and glibenclamide ➤ Try a Free Trial
7,091,223 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
7,960,411 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Bristol Myers Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
128 Luxembourg ➤ Try a Free Trial PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
/2008 Austria ➤ Try a Free Trial PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408
C0006 Belgium ➤ Try a Free Trial PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
C0002 Belgium ➤ Try a Free Trial PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
5 5011-2011 Slovakia ➤ Try a Free Trial FORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY, US
13/034 Ireland ➤ Try a Free Trial APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Deloitte
UBS
Harvard Business School
Medtronic
Daiichi Sankyo
Farmers Insurance
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.